With regard to our hypothesis that intermittent selumetinib may allow for enhanced immune cell function, single nucleus RNA sequencing of serial tumor samples is ongoing and will be reported separately, however preliminary results demonstrated a miniscule population of actively proliferating CD8+ T-cells. The gene discussed is CD8A; the disease is neoplasm.